Literature DB >> 34352360

A discernable increase in the severe acute respiratory syndrome coronavirus 2 R.1 lineage carrying an E484K spike protein mutation in Japan.

Tsuyoshi Sekizuka1, Kentaro Itokawa1, Masanori Hashino1, Kazuhiro Okubo2, Asami Ohnishi3, Keiko Goto4, Hiroyuki Tsukagoshi5, Hayato Ehara6, Ryohei Nomoto7, Makoto Ohnishi8, Makoto Kuroda9.   

Abstract

Three COVID-19 waves in Japan have been characterized by the presence of distinct PANGO lineages (B.1.1. 162, B.1.1.284, and B.1.1.214). Recently, in addition to the B.1.1.7 lineage, which shows 25% abundance, an R.1 lineage carrying the E484K mutation in the spike protein was found to show up to 40% predominance. E484K could be a pivotal amino acid substitution with the potential to mediate immune escape; thus, more attention should be paid to such potential variants of concern to avoid the emergence of mutants of concern. Such comprehensive real-time genome surveillance has become essential for the containment of COVID-19 clusters.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; E484K; Immune escape; Mutation of concern; R.1; SARS-CoV-2; Spatiotemporal distribution; Spike protein

Year:  2021        PMID: 34352360     DOI: 10.1016/j.meegid.2021.105013

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  5 in total

1.  Molecular epidemiological features of SARS-CoV-2 in Japan, 2020-1.

Authors:  Hirotaka Ode; Yoshihiro Nakata; Mami Nagashima; Masaki Hayashi; Takako Yamazaki; Hiroyuki Asakura; Jun Suzuki; Mai Kubota; Kazuhiro Matsuoka; Masakazu Matsuda; Mikiko Mori; Atsuko Sugimoto; Mayumi Imahashi; Yoshiyuki Yokomaku; Kenji Sadamasu; Yasumasa Iwatani
Journal:  Virus Evol       Date:  2022-04-07

Review 2.  Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.

Authors:  Hong Zhou; Wei-Jian Ni; Wei Huang; Zhen Wang; Ming Cai; Yan-Cai Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

3.  Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.

Authors:  Makoto Inada; Masahiro Ishikane; Mari Terada; Akihiro Matsunaga; Kenji Maeda; Noriko Iwamoto; Mugen Ujiie; Satoshi Kutsuna; Shinichiro Morioka; Yukihito Ishizaka; Hiroaki Mitsuya; Norio Ohmagari
Journal:  Int J Infect Dis       Date:  2022-03-16       Impact factor: 12.074

Review 4.  A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

5.  Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020-June 2021.

Authors:  Yasufumi Matsumura; Miki Nagao; Masaki Yamamoto; Yasuhiro Tsuchido; Taro Noguchi; Koh Shinohara; Satomi Yukawa; Hiromi Inoue; Takeshi Ikeda
Journal:  Emerg Infect Dis       Date:  2022-06-16       Impact factor: 16.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.